Abstract: Provided is a pharmaceutical composition comprising a pharmaceutically acceptable organic solvent, a pharmaceutically acceptable surfactant, and a compound according to the following formula: wherein the variables are defined herein. Optionally, the pharmaceutical composition further comprises a co-solvent. Also provided is a method of using the pharmaceutical composition disclosed herein for the treatment of a patient in need thereof.

Abstract: Provided is a pharmaceutical composition comprising a pharmaceutically acceptable organic solvent, a pharmaceutically acceptable surfactant, and a compound according to the following formula: wherein the variables are defined herein. Optionally, the pharmaceutical composition further comprises a co-solvent. Also provided is a method of using the pharmaceutical composition disclosed herein for the treatment of a patient in need thereof.

Abstract: The invention relates to a topical composition and a method for treating psoriasis. The topical composition comprises one or more compound that inhibits the production of IL-12 and IL-23.

Abstract: Methods and apparatuses for interfacing an enterprise customer with a supplier are described herein. In one embodiment, in response to a request received from an enterprise customer via a first interface (e.g., a common or universal interface) of a Web service over the Internet for a service provided by a supplier, processing logic is configured to map the request from a first format compatible with the first interface to a second format compatible with a second interface coupling with a backend system of the supplier. Processing logic invokes a method of the backend system of the supplier via the second interface (e.g., supplier specific interface) to provide the requested service to the enterprise customer using information of the mapped request. The first interface is compatible with the requesting customer and the second interface is a specific interface to the backend system of the supplier. Functionality of mapping and the second interface are maintained by the supplier.

Abstract: Described are new crystalline anhydrous forms of gabapentin formed from gabapentin monohydrate. The new crystalline forms provide advantages in the manufacture of the therapeutic agent.

Abstract: Described are new crystalline anhydrous forms of gabapentin formed from gabapentin monohydrate. The new crystalline forms provide advantages in the manufacture of the therapeutic agent.

Abstract: A pharmaceutical sustained release tablet or tablet layer is formed by making a wet granulation, using povidone (PVP) in water or alcohol-water as the granulating fluid which is mixed with a pharmaceutical active, hydroxyethyl cellulose, a wicking agent e.g. microcrystalline cellulose, then drying and milling the granulation and blending with dry powdered smoothness enhancer, e.g. povidone, erosion promoter, e.g. pregelatinized starch, additional wicking agent, lubricant e.g. magnesium stearate and glidant e.g. silicon dioxide, and compressing the resultant granulation into a tablet with a smooth outer surface, which tablet provides, upon administration, a slow release of the pharmaceutical active.